10 8 月, 2021

Apollomics, Inc. Doses First Patient in Phase I Clinical Trial of APL-102

Foster City, CA, Hangzhou and Shanghai, China, Aug 10, 2021 - (ACN Newswire via SEAPRWire.com) - Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, today announced the successful dosing of the first patient in a Phase I clinical study of APL-102 in patients with advanced solid tumors. The Phase I trial is designed to assess the safety, tolerability and pharmacokinetics of APL-102 delivered via an oral capsule."APL-102 is an internally discovered and developed tyrosine kinase inhibitor targeting multiple oncogenic drivers, and we are excited about advancing it for clinical testing to explore its potential for treating a number of solid tumors;" said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer. "APL-102 is the first of several novel assets planned for clinical development to further expand Apollomics' clinical pipeline in oncology."About APL-102APL-102 is an oral, small molecule multi kinase inhibitor (MTKi) targeting several key oncogenic drivers. APL-102 inhibits several receptor tyrosine kinases (RTKs), including: angiogenesis via vascular endothelial growth factor receptors (VEGFRs), mitogen-activated protein kinase (MAPK) pathway via B-RAF and C-RAF; and colony stimulating factor 1 receptor (CSF1R).Preclinical studies have demonstrated broad and potent antitumor activity in patient-derived xenograft mouse models of liver, breast, colorectal, gastric, esophageal and lung cancers. APL-102 has also shown favorable preclinical pharmacokinetic (PK) and safety profiles with no serious off-target activity observed. APL-102 has the potential to be used as a single agent or in combination with other oncology agents.Apollomics retains worldwide rights to APL-102.About Apollomics Inc.Apollomics Inc. is an innovative biopharmaceutical company committed to the discovery and development of monotherapies and combination therapies of tumor-targeting agents and immuno-oncology agents. The Company's product pipeline has several programs at different stages of development, including novel, humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Apollomics has operating entities in Foster City, Ca., USA, Hangzhou and Shanghai, China. For more information, please visit www.apollomicsinc.com.Contact information of Apollomics:Investor Contact:Wilson W. CheungChief Financial Officer(650) 209-4436wcheung@apollomicsinc.comU.S. Media Contact:Remy BernardaCorporate Communications(415) 203-6386remy.bernarda@apollomicsinc.comChina Media Contact:Porda Havas International Finance Communications GroupKelly FungGeneral Manager(852) 3150 6763kelly.fung@pordahavas.comPhoenix FungVice President(852) 3150 6773phoenix.fung@pordahavas.com Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

10 8 月, 2021

Apollomics, Inc. Doses First Patient in A Phase I Clinical Trial of APL-102

Foster City, CA, Hangzhou and Shanghai, China, Aug 10, 2021 - (ACN Newswire via SEAPRWire.com) - Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, today announced the successful dosing of the first patient in a Phase I clinical study of APL-102 in patients with advanced solid tumors. The Phase I trial is designed to assess the safety, tolerability and pharmacokinetics of APL-102 delivered via an oral capsule."APL-102 is an internally discovered and developed tyrosine kinase inhibitor targeting multiple oncogenic drivers, and we are excited about advancing it for clinical testing to explore its potential for treating a number of solid tumors;" said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer. "APL-102 is the first of several novel assets planned for clinical development to further expand Apollomics' clinical pipeline in oncology."About APL-102APL-102 is an oral, small molecule multi kinase inhibitor (MTKi) targeting several key oncogenic drivers. APL-102 inhibits several receptor tyrosine kinases (RTKs), including: angiogenesis via vascular endothelial growth factor receptors (VEGFRs), mitogen-activated protein kinase (MAPK) pathway via B-RAF and C-RAF; and colony stimulating factor 1 receptor (CSF1R).Preclinical studies have demonstrated broad and potent antitumor activity in patient-derived xenograft mouse models of liver, breast, colorectal, gastric, esophageal and lung cancers. APL-102 has also shown favorable preclinical pharmacokinetic (PK) and safety profiles with no serious off-target activity observed. APL-102 has the potential to be used as a single agent or in combination with other oncology agents.Apollomics retains worldwide rights to APL-102.About Apollomics Inc.Apollomics Inc. is an innovative biopharmaceutical company committed to the discovery and development of monotherapies and combination therapies of tumor-targeting agents and immuno-oncology agents. The Company's product pipeline has several programs at different stages of development, including novel, humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Apollomics has operating entities in Foster City, California, USA, Hangzhou and Shanghai, China. For more information, please visit www.apollomicsinc.com.Contact information of Apollomics:Investor Contact:Wilson W. CheungChief Financial Officer(650) 209-4436wcheung@apollomicsinc.comU.S. Media Contact:Remy BernardaCorporate Communications(415) 203-6386remy.bernarda@apollomicsinc.comChina Media Contact:Porda Havas International Finance Communications GroupKelly FungGeneral Manager(852) 3150 6763kelly.fung@pordahavas.comPhoenix FungVice President(852) 3150 6773phoenix.fung@pordahavas.com Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

16 6 月, 2021

Football: Activist lands on pitch before Germany-France match, ‘injures several fans’

MUNICH, GERMANY (AFP) - A Greenpeace activist crash-landed on the pitch in Munich on Tuesday (June 15) before the Germany-France match at Euro 2020 after his powered parachute microlight struck spidercam cables at the Allianz Arena, with Uefa saying he had "injured several people". The pilot flew over the pitch just before kick-off in the Group F clash with "Kick out oil" written on the canopy of his parachute. However, when the pilot hit television cables above the pitch, it knocked his microlight off balance and he landed on the turf after clipping one of the stands. This is when Uefa said several people were injured and had to be hospitalised. "This inconsiderate act - which could have had very serious consequences for a huge number of people attending - caused injuries to several people attending the game who are now in hospital and law authorities will take the necessary action," European football's governing body said in a statement. "The staging of the match was fortunately not impacted by such a reckless and dangerous action, but several people were injured nonetheless." The activist seemed unhurt and was quickly arrested. The stunt was a protest against German car manufacturer Volkswagen, one of the sponsors of the European Championship, Greenpeace explained in a Twitter post. "Uefa and its partners are fully committed to a sustainable Euro 2020 tournament and many initiatives have been implemented to offset carbon emissions," said Uefa. A Greenpeace protester glides on to the pitch before the match. PHOTO: REUTERS More on this topic Related Story Football: Hummels own goal gifts France 1-0 Euro win over Germany Related Story Football: Ronaldo breaks Euro goalscoring record as Portugal beat Hungary